Increasing prevalence of multidrug-resistant gram-negative organisms has led to a rise in clinically significant infections with these organisms and an increasing therapeutic dilemma. We present a case of a neurosurgical patient who developed ventriculoperitoneal shunt -associated ventriculitis due to ceftazidime-resistant Klebsiella pneumoniae susceptible to cefepime, imipenem, meropenem, and polymyxin B only. The increasing prevalence of clinically significant multidrugglycosides) and/or CRKP (susceptible only to cefepime and imipenem). On postoperative day 64, a change in mental status resistant bacteria has posed new therapeutic challenges. We are now forced to reconsider older therapies when the new antibactesecondary to hydrocephalus required placement of a VPS. After initial improvement, her neurological condition deteriorated, rial agents are rendered ineffective through plasmid-and chromosome-mediated resistance mechanisms. Recently reported nosoand a CSF culture yielded the same CRKP previously isolated from blood and sputum. The VPS was removed and a tempocomial outbreaks of multidrug-resistant gram-negative bacilli have involved patients with pneumonia, bacteremia, and intrarary external ventriculostomy opening was created for administration of intrathecal polymyxin B (50,000 U once daily). In abdominal abscesses [1] [2] [3] [4] [5] [6] [7] . We present a case of nosocomially acquired ceftazidime-resistant Klebsiella pneumoniae (CRKP) inaddition, intravenous meropenem was administered (1 g every 12 hours, as adjusted for impaired renal function). fection causing ventriculitis and ventriculoperitoneal shunt (VPS) infection. The therapeutic challenge was not only treatment of a The patient's mental status improved following removal of the VPS and start of antimicrobial therapy. Administration of multiply resistant organism but also achievement of sufficient bactericidal levels in the CSF to effect a cure.
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polymyxin B was discontinued after a 7-day course, and meropenem was given for 21 days following the first negative CSF culture. Because of her debilitated condition and clinical imCase report provement, the family refused further lumbar punctures to document eradication of infection. However, CRKP has not been The patient, a 55-year-old female school teacher, underwent cultured from her secretions subsequently, and she remained craniotomy and resection of a meningioma. Her postoperative without clinical evidence of infection at 3 months following course was complicated by cerebrovascular hemorrhage, cardiscontinuation of antibiotic therapy. A summary of her hospidiac arrhythmias, renal insufficiency, and severe desquamating tal course appears in which 99.9% killing of the original inoculum could be demon-CSF obtained 12 days after termination of polymyxin B therapy and 1 week before termination of meropenem therapy strated. The procedure for determining bactericidal titers in was sterile. The patient's family refused permission for lumbar CSF was based on recommended guidelines, with use of serum puncture after completion of intravenous therapy. There were [10]. The bactericidal titer was defined as the highest tube no further CRKP-positive cultures of specimens from any site dilution in which 99.9% of the original inoculum was killed.
3 months following cessation of all antibiotic treatment. Etest susceptibility testing was done in accordance with the directions of the manufacturer (AB BIODISK, Solna, Sweden) Discussion to determine MICs of other antimicrobials.
Approximately 60% -70% of cases of meningitis caused by Three sequential isolates from different sources were segram-negative bacilli have occurred following neurosurgical lected for molecular typing by means of pulsed-field gel electrophoresis (PFGE) [11] . Enzyme restriction of bacterial chromosomes was done with use of Xba I (New England Biolabs, ú90% band correlation, as demonstrated in figure 1 [13] .
/ 9c65$$my28
04-06-99 08:58:28 cidas UC: CID penem (table 2) . However, it was considered insufficient as a single form of therapy because of the potential for carbapenem resistance related to loss of an outer-membrane protein among strains of CRKP [22, 23] . In addition, recent evidence suggests that achievable CSF levels of meropenem in patients with hydrocephalus and external ventriculostomy openings may not be bactericidal in the treatment of infection due to multidrug-resistant gram-negative organisms [24] . In view of high-level aminoglycoside resistance, administration of intraventricular polymyxin B was chosen as adjunctive therapy. Suggestions that unidirectional circulation of CSF impedes entry of medications into the ventricular system when instilled via the lumbar space compelled us to administer the agent via an external ventriculostomy opening for optimal effect [20, 25] .
From a large number of related compounds, only two polymyxins, B and E (colistin), have been produced commercially. However, polymyxin B has been used clinically more commonly. It was one of the earliest agents employed in the treatment of gram-negative bacillary meningitis, particularly that due to P. aeruginosa [14, 15, 18, 21, 26 -30] . Polymyxin B demonstrates potent bactericidal activity against most strains of P. aeruginosa, Escherichia coli, Enterobacter spe- poorly into CSF, and the presence of meningeal inflammation does not enhance absorption [31] . CSF levels range from 1.2 to 112 U/mL in children receiving 10,000 to 40,000 U procedures [14 -18] . Antibiotic resistance among isolated pathogens is common, since most gram-negative meningitis is intrathecally (1 mg of pure polymyxin B base is equivalent to 10,000 U of polymyxin B) [31] . Beneficial reduction in nosocomially acquired. Optimal therapy for meningitis requires bactericidal activity of the selected antibiotic, since phagocytocerebral edema and endotoxin production have been demonstrated in experimental studies in rabbits when high-dose insis in the subarachnoid space is ineffective, owing to the relative lack of complement and antibody in infected spinal fluid [19] .
travenous polymyxin is administered concurrently with another antibiotic [32] . Thus, an antibiotic chosen for therapy must be bactericidal against nosocomial gram-negative pathogens and capable of Polymyxin B is nephrotoxic and neurotoxic and has been associated with renal insufficiency, giddiness, and neuromuscucrossing the blood-brain barrier easily. When gram-negative ventriculitis occurs in the presence of ventricular obstruction, lar blockade when used parenterally, and with pain, numbness, paresthesias, confusion, coma, and convulsions when used indirect injection of selected antibiotics into the infected ventricle, plus systemic administration, becomes a primary mode trathecally [14, 21, 26 -29, 31, 33] . The chemical arachnoiditis seen with polymyxin B use is dose-dependent. Parenteral dosof therapy [18, 20] . Experience with gram-positive infections indicates that the most favorable outcome results from removal ing ranges from 2.5 to 3 mg/(kgrd), divided into twice daily doses. The intrathecal dosage is 5 mg once daily for adults, of the infected shunt, creation of an external ventriculostomy opening, and daily administration of systemic and intraventric-2 mg daily for children õ2 years of age, and 3 -4 mg daily for older children [31] . Neurotoxicity is seen when the dosage ular antibiotics [18, 21] .
The case presented above illustrates the complexities associexceeds 5 mg or 50,000 U a day. Use of polymyxin B alone has been successful in therapy ated with nosocomially acquired meningitis due to multidrugresistant bacteria. The patient had been treated with multiple for ú43 patients with meningitis and ventriculitis caused by a number of gram-negative bacteria [14, 16, 17, 21, 26 -28, 30 , broad-spectrum antimicrobial agents, had numerous invasive devices, and had a prolonged stay in an intensive care unit. 31, 34] . Although several authors advocate the separate use of polymyxin B intramuscularly, intravenously, or intrathecally, All are recognized risk factors for colonization and subsequent infection with resistant bacteria, especially CRKP and Pseudocures seemed to be more frequent among patients receiving combination systemic and local therapy (intrathecal or intramonas aeruginosa [2] . Meropenem was chosen for parenteral therapy because its activity is slightly greater than that of imiventricular) or local polymyxin B as an adjunct to other sys- (within 24 -48 hours) when therapy was given in conjunction 9. National Committee for Clinical Laboratory Standards. Methods for dewith surgical repair and/or foreign-body removal [16, 21] . Nev- the combined effect of polymyxin B and meropenem. Our
